Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 4/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
| ▸ | QPCT | Q16769 | 1/20 | 0.35 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | GMNN | O75496 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1853777 | 0.77 | LMNA (0.44) | KDM4EBRD4PARP1ALOX15SMN1; SMN2 | |
| SCHEMBL38687 | 0.76 | ADRA2A (0.41) | KDM4EALOX15QPCTQPCTLMAPT | |
| SCHEMBL30945080 | 0.76 | ADRA2A (0.41) | KDM4EALOX15QPCTQPCTLMAPT | |
| SCHEMBL29199094 | 0.76 | LMNA (0.43) | KDM4EBRD4PARP1ALOX15SMN1; SMN2 | |
| SCHEMBL35938 | 0.74 | LMNA (0.54) | KDM4EBRD4ALOX15SMN1; SMN2MAPT | |
| SCHEMBL29382312 | 0.74 | LMNA (0.54) | KDM4EBRD4ALOX15SMN1; SMN2MAPT | |
| SCHEMBL325052 | 0.73 | PARP1 (0.55) | KDM4EPARP1ALOX15SMN1; SMN2PDPK1 | |
| SCHEMBL31038815 | 0.73 | PSMD14 (0.43) | KDM4EPARP1ALOX15SMN1; SMN2PDPK1 | |
| SCHEMBL202156 | 0.73 | PDPK1 (0.55) | KDM4EPARP1ALOX15SMN1; SMN2PDPK1 | |
| SCHEMBL29508386 | 0.73 | PDPK1 (0.55) | KDM4EPARP1ALOX15SMN1; SMN2PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3350178-A1 | NOVEL IMIDAZO [4,5-C]QUINOLINE AND IMIDAZO [4,5-C][1,5]NAPHTHYRIDINE DERIVATIVES AS LRRK2 INHIBITORS | Pfizer Inc (US) | 2018-07-25 | — | — | EP | claimed |
| WO-2017046675-A1 | NOVEL IMIDAZO [4,5-C] QUINOLINE AND IMIDAZO [4,5-C][1,5] NAPHTHYRIDINE DERIVATIVES AS LRRK2 INHIBITORS | PFIZER INC. (US) | 2017-03-23 | — | — | WO | claimed |
| EP-1833827-A2 | PROCESS FOR PREPARING 2-METHYL-1-(2-METHYLPROPYL)-1H-IMIDAZOÝ4,5-C¨Ý1,5¨NAPHTHYRIDIN-4-AMINE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-09-19 | — | — | EP | claimed |
| WO-2006074046-A2 | PROCESS FOR PREPARING 2-METHYL-1-(2-METHYLPROPYL)-1H-IMIDAZO[4,5-C][1,5]NAPHTHYRIDIN-4-AMINE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-07-13 | — | — | WO | claimed |
| EP-4551251-A2 | CNS TARGETING COMPLEXES AND USES THEREOF | Dyne Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024011150-A2 | CNS TARGETING COMPLEXES AND USES THEREOF | DYNE THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| EP-3350178-B1 | NOVEL IMIDAZO [4,5-C]QUINOLINE AND IMIDAZO [4,5-C][1,5]NAPHTHYRIDINE DERIVATIVES AS LRRK2 INHIBITORS | PFIZER (US) | 2021-10-20 | — | — | EP | disclosed |
| US-10766896-B2 | Imidazo[4,5-c] ring compounds containing guanidine substituted benzamide groups | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2020-09-08 | — | — | US | disclosed |
| US-20200087298-A1 | Imidazo[4,5-c] Ring Compounds Containing Guanidine Substituted Benzamide Groups | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2020-03-19 | — | — | US | disclosed |
| US-10487081-B2 | Guanidine substituted imidazo[4,5-c] ring compounds | 3M INNOVATION PROPERTIES COMPANY (US) | 2019-11-26 | — | — | US | disclosed |
| US-10414779-B2 | Fused [1,2]imidazo[4,5-C] ring compounds substituted with guanidino groups | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2019-09-17 | — | — | US | disclosed |
| EP-3504215-A1 | FUSED [1,2]IMIDAZO[4,5-c]RING COMPOUNDS SUBSTITUTED WITH GUANIDINO GROUPS | 3M Innovative Properties Company (US) | 2019-07-03 | — | — | EP | disclosed |
| US-20030083500-A1 | Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-05-01 | — | — | US | disclosed |
| US-6518280-B2 | Antiviral and antitumor properties; immunomodulators and for inducing cytokine biosynthesis in animals | 3M INNOVATIVE PROPERTIES COMPANY | 2003-02-11 | — | — | US | disclosed |
| US-6514985-B1 | Induce the biosynthesis of cytokines such as interferon and tumor necrosis factor; exhibit antiviral and antitumor properties | 3M INNOVATIVE PROPERTIES COMPANY | 2003-02-04 | — | — | US | disclosed |
| US-20020173654-A1 | Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2002-11-21 | — | — | US | disclosed |
| US-20020173653-A1 | Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2002-11-21 | — | — | US | disclosed |
| US-6194425-B1 | VIRICIDES, ANTITUMOR AGENTS | 3M INNOVATIVE PROPERTIES COMPANY | 2001-02-27 | — | — | US | disclosed |
| EP-1040112-A1 | IMIDAZONAPHTHYRIDINES AND THEIR USE IN INDUCING CYTOKINE BIOSYNTHESIS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 2000-10-04 | — | — | EP | disclosed |
| WO-1999029693-A1 | IMIDAZONAPHTHYRIDINES AND THEIR USE IN INDUCING CYTOKINE BIOSYNTHESIS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1999-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083500-A1 | Imidazonaphthyridines | IFNG, IRF3, IFNAR1 | KDM4E 4437/4885BRD4 1200/4885PARP1 1457/4885 |
| US-10487081-B2 | Guanidine substituted imidazo[4,5-c] ring compounds | IFNG, IRF3, IL4 | KDM4E 1015/4885BRD4 136/4885PARP1 2764/4885 |
| US-20200087298-A1 | Imidazo[4,5-c] Ring Compounds Containing Guanidine Substituted Benzamide Groups | IL4, IFNG, IFNAR1 | KDM4E 1023/4885BRD4 47/4885PARP1 2257/4885 |
| US-20020173653-A1 | Imidazonaphthyridines | IFNG, IRF3, IFNAR1 | KDM4E 4437/4885BRD4 1200/4885PARP1 1457/4885 |
| US-20020173654-A1 | Imidazonaphthyridines | IFNG, IRF3, IFNAR1 | KDM4E 4437/4885BRD4 1200/4885PARP1 1457/4885 |
| US-10414779-B2 | Fused [1,2]imidazo[4,5-C] ring compounds substituted with guanidino groups | IFNG, IRF3, STING1 | KDM4E 2209/4885BRD4 143/4885PARP1 3475/4885 |
| US-10766896-B2 | Imidazo[4,5-c] ring compounds containing guanidine substituted benzamide groups | IL4, IFNG, IFNAR1 | KDM4E 1023/4885BRD4 47/4885PARP1 2257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.